PTPA and neoplasm: Early studies using okadaic acid—a serine-threonine phosphatase inhibitor that targets the catalytic PP2Ac subunit—increased tumor formation in a cutaneous carcinogenesis challenge and provided early biochemical support for a tumor suppressive role of PP2A [27,28].